Article ID Journal Published Year Pages File Type
2172667 Cytotherapy 2007 11 Pages PDF
Abstract
These data suggest that most leukemic progenitors of CD34+ patients do not express CD33. In contrast, CD34− AML primitive leukemic progenitors may be CD33+. CD34− AML patients could potentially benefit most from CD33-targeted therapies or purging.
Related Topics
Life Sciences Biochemistry, Genetics and Molecular Biology Cell Biology
Authors
, , ,